Short-Term Risk Factors for Bone Loss in Multiple Sclerosis: A Prospective Study and Literature Review.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: A.Z. has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Novartis, Sanofi‐Genzyme, Janssen, Bristol Myers Squibb, and Teva. H.H. has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Bristol Myers Squibb, Horizon, Janssen, Merck, Novartis, Sanofi‐Genzyme, Siemens, Teva, and received honoraria for acting as a consultant for A‐med, Biogen, Bristol Myers Squibb, Novartis, Roche, Sanofi‐Genzyme, and Teva. J.W. has nothing to disclose. R.B. has participated in meetings sponsored by or received travel grants from Novartis, Janssen‐Cilag, Merck, and Sanofi‐Genzyme. Received honoraria from Janssen‐Cilag and Biogen. K.B. has participated in meetings sponsored by and received travel funding or speaker honoraria from Roche, Teva, Merck, Biogen, Sanofi, and Novartis. He is an associate editor of Frontiers in Immunology/Neurology, Section Multiple Sclerosis and Neuroimmunology. M.A. received speaker honoraria, honoraria for consulting and/or travel grants from Biogen, Novartis, Merck, Sanofi, Horizon Therapeutics/Amgen, and Zentiva. M.S. has participated in meetings sponsored by or received travel grants from Novartis, Sanofi‐Genzyme, and Amgen. G.B. has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Janssen, Lilly, Medwhizz, Merck, Novartis, Roche, Sanofi‐Genzyme, and Teva, and received honoraria for consulting Adivo Associates, Biogen, Celgene/BMS, Janssen, Merck, Novartis, Roche, Sanofi‐Genzyme, and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. He serves on the Executive Committee of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). A.S.K. has nothing to disclose. A.G. has nothing to disclose. B.W. has nothing to disclose. A.T. has nothing to disclose. T.B. has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Amgen, Allergan, Bayer, Biogen, Bionorica, BMS, Genesis, GSK, GW/Jazz Pharma, Horizon, Janssen, MedDay, Merck, Neuraxpharma, Novartis, Octapharma, Roche, Sandoz, Sanofi, Teva, TG Therapeutics, and UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, BMS, Merck, Novartis, Roche, Sanofi, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi, and Teva. F.D. has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, A‐Med, Amgen/Horizon, Biogen, BMS, Sanofi, Janssen, Laurea Group, Medwhizz, Merck, Novartis Pharma, Neuraxpharm, Roche, Sandoz, and Teva. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders) and review editor of Frontiers in Neurology. F.D.P. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations), or travel funding from Amgen, Bayer, Biogen, Celgene, BMS, Horizon, Merck, Novartis, Sanofi‐Genzyme, Teva, and Roche. 15. Calcif Tissue Int. 2025 Feb 21;116(1):42. doi: 10.1007/s00223-025-01349-x. Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab. Pollastri F(1), Fassio A(2), Ferraro PM(3), Andreola S(3), Gambaro G(3), Spasiano A(3), Caletti C(3), Stefani L(3), Gatti M(4), Fabbrini P(4), Rossini M(2), Galvagni I(2), Gatti D(2), Adami G(2), Viapiana O(2). Author information: (1)Rheumatology Unit, University of Verona, Policlinico GB Rossi, 37134, Verona, Italy. franpollastri@yahoo.it. (2)Rheumatology Unit, University of Verona, Policlinico GB Rossi, 37134, Verona, Italy. (3)Nephrology Unit, University of Verona, Verona, Italy. (4)Department of Nephrology and Dialysis, Ospedale Bassini, ASST Nord Milano-Cinisello Balsamo, Milan, Italy. Kidney transplant recipients (KTRs) have an elevated fracture risk. While dual-energy X-ray absorptiometry (DXA) is commonly used to assess areal bone mineral density (aBMD), it does not capture all aspects of bone quality. We investigated the long-term effects on bone DXA-derived indices of bone quality in KTRs treated with denosumab and untreated with denosumab. This is a retrospective study, including KTRs treated with denosumab and untreated age and sex-matched KTR controls. DXA-derived parameters, including trabecular bone score (TBS) and 3D-DXA parameters, were measured at the lumbar spine and femur at baseline and after four years. Hierarchical linear models were used to assess the between-group effect of treatment over time, also adjusting for site-specific aBMDs. We enrolled 23 KTRs treated with denosumab and 23 KTR denosumab-untreated KTRs. Significant between-group differences over time in favor of the denosumab group were observed for TBS (0.843, 95%CI 0.439; 1.248,p